diff --git a/archive-covid-19/10 July, 2023.html b/archive-covid-19/10 July, 2023.html new file mode 100644 index 0000000..14467ca --- /dev/null +++ b/archive-covid-19/10 July, 2023.html @@ -0,0 +1,176 @@ + +
+ + + ++Antimicrobial peptides (AMPs) are a complex network of 10-100 amino acid sequence molecules, widely distributed in Nature. Even though more than 300 AMPs have been described in mammals, cathelicidins and defensins remain the most investigated to date. Some publications examined the role of AMPs in COVID-19, but the findings are preliminary and in vivo studies are still lacking. Here, we report the plasma levels of five AMPs (LL-37, α-defensin 1, α-defensin 3, β-defensin 1 and β-defensin 3) and five cytokines (tumor necrosis factor-α, interleukin-1β, interleukin-6, interleukin-10, interferon-gamma and monocyte chemoattractant protein-1), in 15 healthy volunteers, 36 COVID-19 patients without Acute Kidney Injury (AKI) and 17 COVID-19 patients with AKI, since AKI is a well-known marker of worse prognosis in Sars-CoV-2 infections. We found increased levels of α-defensin 1, α-defensin 3 and β-defensin 3, but not LL-37 or β-defensin 3, in our COVID-19 population, when compared with the healthy controls, in conjunction with higher levels of interleukin-6, interleukin-10, interferon-gamma and monocyte chemoattractant protein-1, putting in evidence that these AMPs and cytokines may have an important role in the systemic inflammatory response and tissue damage that characterizes severe COVID-19. +
++Objectives: Africa has experienced fewer coronavirus disease 2019 (COVID-19) cases and deaths than other regions, with a contrasting epidemiological situation between countries, raising questions regarding the determinants of disease spread in Africa. Method: We built a susceptible-exposed-infected-recovered model including COVID-19 mortality data where recovery class is structured by specific immunization and modeled by a partial differential equation considering the opposed effects of immunity decline and immunization. This model was applied to Tunisia, Senegal, and Madagascar. Finding: Senegal and Tunisia experienced two epidemic phases. Initially, infections emerged in naive individuals and were limited by social distancing. Variants of concern (VOCs) were also introduced. The second phase was characterized by successive epidemic waves driven by new VOCs that escaped host immunity. Meanwhile, Madagascar demonstrated a different profile, characterized by longer intervals between epidemic waves, increasing the pool of susceptible individuals who had lost their protective immunity. The impact of vaccination in Tunisia and Senegal on model parameters was evaluated. Interpretation: Loss of immunity and vaccination-induced immunity have played crucial role in controlling the African pandemic. Severe acute respiratory syndrome coronavirus 2 has become endemic now and will continue to circulate in African populations. However, previous infections provide significant protection against severe diseases, thus providing a basis for future vaccination strategies. +
+Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine - Condition: COVID-19
Intervention: Biological: SARS-CoV-2 Subunit Recombinant Protein Vaccine
Sponsor: PT Bio Farma
Not yet recruiting
Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial - Condition: COVID-19
Interventions: Drug: Ivermectin Tablets; Drug: Colchicine 0.5 MG; Drug: Standared managment
Sponsor: Ain Shams University
Completed
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines - Conditions: COVID-19; SARS-CoV-2 Infection
Interventions: Biological: SCTV01E-2; Biological: SCTV01E
Sponsor: Sinocelltech Ltd.
Not yet recruiting
COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists - Condition: COVID-19
Interventions: Behavioral: Standard implementation webinar and online training; Behavioral: Virtual facilitation
Sponsors: University of North Carolina, Chapel Hill; University of Arkansas; University of South Carolina; National Institute on Minority Health and Health Disparities (NIMHD)
Not yet recruiting
Developing an Effective Intervention to Address Post-Corona-Virus-Disease-2019 Balance Disorders, Weakness and Muscle Fatigue in Individuals Aged 65+ - Condition: COVID-19
Intervention: Device: Resistance Training
Sponsor: Józef Piłsudski University of Physical Education
Recruiting
LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients - Conditions: COVID-19; Hospitalized COVID-19 Patients
Interventions: Drug: Lopinavir / Ritonavir; Drug: Remdesivir (RDV); Drug: Tocilizumab; Other: Corticosteroid Therapy-enhanced Standard Care (CTSC)
Sponsors: Lebanese University; Hospital Saydet Zgharta University Medical Center
Recruiting
Multimodal Long Covid19 - Condition: Long COVID-19 Syndrome
Intervention: Other: Multimodal intervention in Long Covid19
Sponsors: Universidad de Magallanes; Teaching Assistance and Research Center of the University of Magallanes CADI-UMAG; Clinical Hospital Dr. Lautaro Navarro Avaria
Active, not recruiting
Comprehensive Imaging Exam of Convalesced COVID-19 Patients - Conditions: COVID-19; COVID Long-Haul
Interventions: Other: Magnetic Resonance Imaging; Other: Ultra-High Resolution Computed Tomography (CT) Scan
Sponsors: Johns Hopkins University; Canon Medical Systems, USA
Enrolling by invitation
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) - Conditions: COVID-19 Pandemic; COVID-19 Vaccines
Interventions: Biological: Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg; Biological: CoronaVac Biofarma COVID-1 9 Vaccine 3 µg
Sponsors: Dr. Soetomo General Hospital; Indonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, Indonesia
Recruiting
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults - Condition: COVID-19
Interventions: Biological: SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection; Biological: SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Not yet recruiting
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002 - Condition: COVID-19
Interventions: Biological: LYB002V14; Biological: LYB002V14A; Biological: LYB002CA
Sponsors: Guangzhou Patronus Biotech Co., Ltd.; Yantai Patronus Biotech Co., Ltd.; Affiliated Hospital of North Sichuan Medical College
Active, not recruiting
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines - Condition: COVID-19
Interventions: Biological: NVX-CoV2373 (5μg); Biological: NVX-CoV2601 (5μg); Biological: NVX-CoV2601(5μg); Biological: NVX-CoV2601 (35μg); Biological: NVX-CoV2601(35μg); Biological: NVX-CoV2601(50μg); Biological: Bivalent BA.4/5
Sponsor: Novavax
Not yet recruiting
Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease - Conditions: COVID-19; Renal Insufficiency, Chronic
Intervention: Drug: Nirmatrelvir/ritonavir
Sponsor: Chinese PLA General Hospital
Recruiting
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001 - Conditions: COVID-19; Vaccine Reaction
Interventions: Biological: LYB001; Biological: CoronaVac
Sponsors: Guangzhou Patronus Biotech Co., Ltd.; Yantai Patronus Biotech Co., Ltd.; Affiliated Hospital of North Sichuan Medical College
Active, not recruiting
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome - Condition: Post-Acute COVID-19 Syndrome
Interventions: Drug: Placebo; Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret]
Sponsor: Hellenic Institute for the Study of Sepsis
Not yet recruiting
Garbage in, garbage out: how reliable training data improved a virtual screening approach against SARS-CoV-2 MPro - Introduction: The identification of chemical compounds that interfere with SARS-CoV-2 replication continues to be a priority in several academic and pharmaceutical laboratories. Computational tools and approaches have the power to integrate, process and analyze multiple data in a short time. However, these initiatives may yield unrealistic results if the applied models are not inferred from reliable data and the resulting predictions are not confirmed by experimental evidence. Methods: We…
Virtual high-throughput screening: Potential inhibitors targeting aminopeptidase N (CD13) and PIKfyve for SARS-CoV-2 - Since the outbreak of the novel coronavirus nearly 3 years ago, the world’s public health has been under constant threat. At the same time, people’s travel and social interaction have also been greatly affected. The study focused on the potential host targets of SARS-CoV-2, CD13, and PIKfyve, which may be involved in viral infection and the viral/cell membrane fusion stage of SARS-CoV-2 in humans. In this study, electronic virtual high-throughput screening for CD13 and PIKfyve was conducted…
Investigation of oxidative, inflammatory and apoptotic effects of favipiravir use alone and combined with vitamin C on brain tissue of elderly rats - Favipiravir is a nucleoside analogue antiviral drug and inhibits the replication of many RNA viruses, especially influenza viruses. Favipiravir has also been used to treat patients with mild to moderate COVID-19 disease. However, various side effects, including neurological side effects, have been reported related to the use of favipiravir. Therefore, in this study, we aimed to investigate the possible effects of favipiravir alone or in combination with vitamin C on aged rats’ brain tissue and…
In silico identification of D449-0032 compound as a putative SARS-CoV-2 Mpro inhibitor - The SARS-CoV-2 pandemic originated the urgency in developing therapeutic resources for the treatment of COVID-19. Despite the current availability of vaccines and some antivirals, the occurence of severe cases of the disease and the risk of the emergence of new virus variants still motivate research in this field. In this context, this study aimed at the computational prospection of likely inhibitors of the main protease (M^(pro)) of SARS-CoV-2 since inhibiting this enzyme leads to disruption of…
Synthesis of multivalent sialyllactose-conjugated PAMAM dendrimers: Binding to SARS-CoV-2 spike protein and influenza hemagglutinin - Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) and influenza viruses have spread around the world at an unprecedented rate. Despite multiple vaccines, new variants of SARS-CoV-2 and influenza have caused a remarkable level of pathogenesis. The development of effective antiviral drugs to treat SARS-CoV-2 and influenza remains a high priority. Inhibiting viral cell surface attachment represents an early and efficient means to block virus infection. Sialyl glycoconjugates, on…
Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models - The weakened protective efficacy of COVID-19 vaccines and antibodies caused by SARS-CoV-2 variants presents a global health emergency, which underscores the urgent need for universal therapeutic antibody intervention for clinical patients. Here, we screened three alpacas-derived nanobodies (Nbs) with neutralizing activity from twenty RBD-specific Nbs. The three Nbs were fused with the Fc domain of human IgG, namely aVHH-11-Fc, aVHH-13-Fc and aVHH-14-Fc, which could specifically bind RBD protein…
Janus kinase inhibition in juvenile idiopathic arthritis - No abstract
Patch-clamp studies and cell viability assays suggest a distinct site for viroporin inhibitors on the E protein of SARS-CoV-2 - CONCLUSIONS: This study demonstrates direct inhibition of the SARS-CoV-2 E protein by classical viroporin inhibitors. Ivermectin and milbemycin inhibit the E protein channel but their cytotoxicity argues against clinical application.
Structural basis for the inhibition of coronaviral main proteases by ensitrelvir - Main protease (M^(pro)) is a highly conserved cysteine protease that plays a vital role in the replication of coronaviruses, making it an attractive pan-coronaviral therapeutic target. Ensitrelvir (S-217622), developed by Shionogi, is the first orally active non-covalent, non-peptidic SARS-CoV-2 M^(pro) inhibitor, which also displays antiviral efficacy against other human coronaviruses as well as SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs). Here, we report the crystal…
Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion - CONCLUSIONS: Kae prevents SARS-CoV-2 infection by blocking membrane fusion and possesses a broad-spectrum anti-fusion ability. These findings provide valuable insights into potential benefits of Kae-containing botanical products as a complementary prophylaxis, especially during the waves of breakthrough infections and re-infections.
Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 Annual Meeting - The 2022 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held from July 14 to 17, 2022, in New York City, New York, USA, and was attended by 420 rheumatologists, dermatologists, basic scientists, allied health professionals, patient research partners, and industry partners from 31 countries. A GRAPPA executive retreat, a Trainee Symposium, and the Patient Research Partners Network meeting were held prior to the annual meeting….
NETosis promotes chronic inflammation and fibrosis in systemic lupus erythematosus and COVID-19 - Pulmonary fibrosis, a serious complication of systemic lupus erythematosus (SLE) and coronavirus disease 2019 (COVID-19), leads to irreversible lung damage. However, the underlying mechanism of this condition remains unclear. In this study, we revealed the landscape of transcriptional changes in lung biopsies from individuals with SLE, COVID-19-induced pulmonary fibrosis, and idiopathic pulmonary fibrosis (IPF) using histopathology and RNA sequencing, respectively. Despite the diverse etiologies…
Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes - The evolving SARS-CoV-2 Omicron strain has repeatedly caused widespread disease epidemics, and effective antibody drugs continue to be in short supply. Here, we identified a batch of nanobodies with high affinity for receptor binding domain (RBD) of SARS-CoV-2 spike protein, separated them into three classes using high performance liquid chromatography (HPLC), and then resolved the crystal structures of the ternary complexes of two non-competing nanobodies (NB1C6 and NB1B5) with RBD using X-ray…
Repurposing the Medicines for Malaria Venture’s COVID Box to discover potent inhibitors of Toxoplasma gondii, and in vivo efficacy evaluation of almitrine bismesylate (MMV1804175) in chronically infected mice - Toxoplasmosis, caused by the obligate intracellular parasite Toxoplasma gondii, affects about one-third of the world’s population and can cause severe congenital, neurological and ocular issues. Current treatment options are limited, and there are no human vaccines available to prevent transmission. Drug repurposing has been effective in identifying anti-T. gondii drugs. In this study, the screening of the COVID Box, a compilation of 160 compounds provided by the “Medicines for Malaria Venture”…
Targeting 2-Oxoglutarate-Dependent Dioxygenases Promotes Metabolic Reprogramming That Protects against Lethal SARS-CoV-2 Infection in the K18-hACE2 Transgenic Mouse Model - Dysregulation of host metabolism is a feature of lethal SARS-CoV-2 infection. Perturbations in α-ketoglutarate levels can elicit metabolic reprogramming through 2-oxoglutarate-dependent dioxygenases (2-ODDGs), leading to stabilization of the transcription factor HIF-1α. HIF1-α activation has been reported to promote antiviral mechanisms against SARS-CoV-2 through direct regulation of ACE2 expression (a receptor required for viral entry). However, given the numerous pathways HIF-1α serves to…
What to Do with Climate Emotions - If the goal is to insure that the planet remains habitable, what is the right degree of panic, and how do you bear it? - link
Wes Moore Would Like to Make History - Maryland’s first Black governor talks about his surprise win, what working in banking taught him about power, his grandmother’s advice, and the importance of service. - link
The Alternative Facts of Robert F. Kennedy, Jr. - The Democratic Presidential candidate talks about his right-wing admirers, his distrust of scientists and the media, and his belief that the C.I.A. was involved in J.F.K.’s death. - link
The Conspiracies of Robert F. Kennedy, Jr. - The anti-vaccine activist and litigator with a famous name and a long history of addiction has decided to run for President. David Remnick probes what his candidacy is all about. - link
To Save the Planet, Should We Really Be Moving Slower? - The degrowth movement makes a comeback. - link
+Two economists on why progress requires more than technological innovation alone +
++It’s tempting to imagine progress strictly as a technological science, where both its history and future are stories of humanity becoming more prosperous one major innovation at a time. But that would be a mistake, according to MIT economists Daron Acemoglu and Simon Johnson in their new book, Power and Progress: Our 1000-Year Struggle Over Technology & Prosperity. +
++The book traverses a millennium of disruptive technologies, from medieval agriculture and ship design all the way up to the foothills of generative AI. Along the way, they argue that innovation has proven just as likely to cause misery as it has prosperity. On their list of examples is the cotton gin, which turned the United States into the world’s largest cotton exporter, while also deepening a system of enslavement that spread across the American South. When prosperity does win out, it’s usually because citizens organized to demand more equitable arrangements than those enriching a narrow elite. +
++“A thousand years of history and contemporary evidence make one thing abundantly clear: there is nothing automatic about new technologies bringing widespread prosperity. Whether they do or not is an economic, social, and political choice,” they write. +
++They are no more sanguine about the future of the next great innovation: AI. In their view, translating innovation around AI into shared prosperity will require countervailing powers, like a labor movement demanding worker-friendly automation, and a civil society movement upholding a more egalitarian vision for the kind of society AI can help create. +
++“We’re addressing the core problem that no one else has talked about: It’s about the vision that drives how you imagine the future,” Johnson told me. “And a lot of our argumentation and policy proposals are designed to help people understand how easy it would be to change that vision.” +
++I spoke with Acemoglu and Johnson about what choices steered innovation toward progress in the past, and what specific policies their trek through history suggests we might consider today. A transcript, edited for length and clarity, follows. +
++Your book argues that technological progress, alone, does not automatically lead to shared prosperity. What else is necessary to turn innovation toward the common good? +
++Daron Acemoglu: The first key ingredient that we argue for technological advances translating into something resembling shared progress is that their direction should not be just automation, or sidelining humans. That’s critical for keeping humans in the loop and increasing their contribution to production, and an institutional structure that enables them to actually get the returns out of that. And second, vision, which is critical, because we argue there’s nothing inevitable about any of those things. Both technologies and institutions are shaped by the visions of powerful actors as well as other political balances. +
++You focus on “vision” throughout the book, but it’s sort of a nebulous idea. Are there any historical examples that show how much of an impact guiding visions can have? +
++Simon Johnson: The reason we start in the medieval period is because we’re quite convinced that the so-called Dark Ages were not particularly dark from the point of view of creativity and innovation. From 1,000 years ago, they were actually very creative, with lots of inventions across agriculture and commerce. But the prevailing vision of that medieval period was one where you had a small elite who argued that they had a divinely endowed power, and took pretty much all the proceeds of that higher productivity and put them into monumental cathedrals. +
++Those cathedrals did not increase productivity; they didn’t improve public health. They were symbols of oppression. You can argue that it was an alternative vision breaking away from that medieval, religious-oriented, top-down control vision that was necessary, though not sufficient, for the beginnings of the modern era and industrialization. +
++What struck me about your chapter on the Industrial Revolution was the huge gap between the introduction of new technologies and the beginnings of anything that resembled shared prosperity. You argue that for the better part of a century, many people’s lives just became more miserable. +
++Simon Johnson: You can argue about when exactly the Industrial Revolution got started. I like the 1720s because that’s when the first big silk mill was built just outside Derby [an English city]. That began putting people into factories with machines that were controlled by an employer. So the 1720s is a good starting point. +
++Young children were working 18 hours a day pushing coal carts with their heads deep underground. We know that was happening in the 1840s because that was a matter of investigation by royal commission. Because it wasn’t illegal, everyone involved was quite candid about it, and said, “Look, that’s what you need in order for a coal industry to exist.” +
++So that’s 120 years where you cannot say that these 6-year-old children were living better. Some people argue a little about wages, but living conditions and public health in those cities were dreadful. And after the 1840s, there was a shift in thinking. It wasn’t particularly altruistic, it was more “My god, we have infectious disease rampant in Manchester because there’s no toilets. What are we going to do about it?” Consequently, there was a reimagining of how technology could be applied, including the modern sanitation movement, which was by far the No. 1 breakthrough in the use of technology in the 19th century. And this coincides with trade unions beginning to get organized and pressure on the political elite to allow wages to rise. +
++So if I said to you that generative AI is here, and that you and your families will be better off in 120 years, I think people should be fairly unsatisfied with that. Why do we have to wait so long? +
++Daron Acemoglu: It’s sort of remarkable how consistent this view is among many economists, policymakers, and even the Democratic Party: when you have better technologies, the costs are “transitional.” What that encapsulates is that there’s often an implicit belief that [shared prosperity] is automatic, but it might take time. +
++The biggest target for Simon and I is that there is nothing automatic about it. But the automatic view gives you a real sense of comfort. Wealth inequality may be horrible, democracy may be in a difficult position today, generative AI may create lots of disruptions, but we’ll work it out. +
++So if there was nothing automatic about that long period of industrial-born misery eventually turning into shared prosperity, why did it eventually begin to shift for the better? +
++Daron Acemoglu: Cities and factories created huge amounts of misery, but they also changed how easy it was for people to organize. Once hundreds of thousands of working people were concentrated in cities and workplaces, the demand for representation grew difficult to turn down. +
++But there were other factors, like the redirection of technological change. The next phase of industrial technology in heavy industry like chemicals and steel opened up new opportunities for investing in human skills. American technologies had to prioritize making unskilled workers more productive, and once that got started it spread around the world. +
++You make a distinction between two kinds of automation. One, “so-so automation,” just replaces workers outright. The other, “machine usefulness,” either complements their skills or creates new tasks for workers. You argue that we should aim for the latter — what’s an example? +
++Simon Johnson: The central example is when Ford comes to Detroit and takes on car production. In 1900, the US car industry produced about 3,500 cars a year, mostly artisanal. Henry Ford put car production on the assembly line and increased productivity more than 100-fold. He also, of course, automated many of the jobs that had previously been done by those artisans. However, what he did, along with the managers and engineers and suppliers and consumers, was create this enormous industry. By the end of the 1920s, the US was making between 2 and 3 million cars a year, employing 400,000 people. Most of those people had tasks, which led to jobs that had never been done by any human ever. And by the way, unions became stronger and pushed for wages. +
++So we are in no way opposed to automation. We are encouraging the seeking out and development of those human-complementary innovations and uses of machines, because it’s that increased demand for labor that is the heart of high wages and shared prosperity. +
++Labor movements and unions were the basis of those countervailing social powers in 19th-century America. Today, despite some high-profile media organizing and strike waves, union membership remains at an all-time low in the US. What role do you see for the labor movement going forward? +
++Daron Acemoglu: The future of the labor movement is open. We are convinced you need workers’ voice. It’s not good when AI regulation is discussed by senators and the CEOs of the chief tech companies and nobody else. And there are many things that are wrong. Sectoral unions would be better [than individual workplace unions, as is common in the US], but you might need a broader civil society movement to complement the labor movement, and the labor movement itself needs to find new organizational forms. +
++You surveyed 1,000 years of history in order to argue that AI will not automatically lead to shared prosperity and that we’ll need specific policy interventions to achieve that. Could you each share one policy that you’ve come to believe should be a part of that debate? +
++Daron Acemoglu: One that I will put on the table is evening out the taxation of labor and capital. Our tax code creates artificial incentives for firms to use capital instead of labor. You can have bipartisan support if it’s presented the right way: not taxing businesses more, but trying to create more opportunities for labor. Corporate income taxes would be one channel. But first, I would start with removing some of the most aggressive depreciation allowances [a tax deduction that allows businesses to recover the annual cost of property or equipment use] which essentially enable firms to write off a lot of their digital and equipment investments. +
++Simon Johnson: I’ll suggest two. One is surveillance. In the case of employment, if surveillance actually makes your life more stressful, and makes you more likely to cause an accident or injure yourself, that is something that falls within the sphere of reasonable regulation. We should consider negotiating safeguards on surveillance across G7 allies and other industrial democracies. +
++The second one is: Show me the new tasks. How do we get more invention in that direction? We know how to do this; we’ve seen it many times since 1940 in the United States. You put some federal government money in. +
++The interesting thing about federal money is that it’s catalytic; you don’t have to put that much money in. If you look at the Human Genome Project, for example, which was turned down by venture capitalists in the 1980s because they said, “Hey, great idea, but we don’t know how to benefit from it because it will be general knowledge,” it became a government-funded project. It cost about $10 billion, creating an industry that employed 200,000 people, and changed the world repeatedly. So federal money applied in this strategic, purposeful manner, can change everything. +
++Their book, Power and Progress: Our 1000-Year Struggle Over Technology & Prosperity, is available now. +
+The Vox guide to navigating the world, the country, and your own backyard. +
++After three years of pandemic life, travel is back in a big way this summer. +
++More people are taking trips this summer after putting plans on hold, but climate change, social media-fueled overcrowding, rising costs, and other factors have converged to make travel decisions more fraught than ever. For Vox’s first-ever travel guide, we wanted to answer some of your most pressing questions about travel now, from how to navigate the many decisions and ethical dilemmas around traveling, to explaining why our travel and transportation systems are designed the way they are. +
++Each week throughout July, we’ll be publishing new articles and videos answering your biggest travel questions. Stay tuned for more! — Nisha Chittal, managing editor +
++CREDITS +
++Managing editor: Nisha Chittal | Editors: Alanna Okun, Izzie Ramirez, Marina Bolotnikova, Meredith Haggerty, Bryan Walsh | Contributors: Allie Volpe, Kenny Torrella, Rebecca Jennings, Emily Stewart, Julieta Cardenas, Carlye Wisel, Paulette Perhach | Art Director: Paige Vickers | Illustrations: Naomi Elliott | Style & Standards: Tanya Pai, Caity PenzeyMoog, Kim Eggleston, Elizabeth Crane, Sarah Schweppe | Video: Adam Freelander, Bridgett Henwood, Cath Spangler, Christophe Haubursin, Coleman Lowndes, Edward Vega, Joey Sendaydiego, Kim Mas, Kristen Williamson, Laura Bult, Liz Scheltens, Matt Dunne, Mona Lalwani, Valerie Lapinski, Dean Peterson, Estelle Caswell | Audience: Gabby Fernandez, Jayne A. Quan +
+This swoopy, swishy paint job defines the RV aesthetic. +
++You’ve seen it on the highway: a giant RV, lumbering by with its exterior totally covered in swishes and swoops. Those swoopy lines of paint seem to grace the sides of every recreational vehicle, and for decades they’ve defined the RV aesthetic. But where did they come from? +
++In this video, producer Estelle Caswell heads to Elkhart, Indiana — the global capital of RV production — to investigate why these swoops are everywhere, and whether they’re here to stay. While there, she explores Elkhart’s RV history museum and library, and speaks to RV designers who love and hate the swoops. +
++Will RV makers be forced to change their infamous look to appeal to younger generations obsessed with clean aesthetics? Or are we stuck with this look for the next 20 years? Check out the video to find out. +
++This video is the first of five in our travel design miniseries. Tune in next week on our YouTube channel to see why train travel has a bad reputation in the US. +
The upcoming Asian Games will be challenging, says Indian TT player Sreeja Akula -
Grand Chess Tour: Carlsen wins; Gukesh finishes 5th, Anand settles for 7th in Blitz event - Carlsen capped off an incredible blitz performance to win the top prize a score of 26 points out of a possible 36, taking home a first-place prize of $40,000
Archer Salunkhe is recurve men’s under-21 individual champion - He was the first Indian male archer to achieve the feat
Australia’s Warner in spotlight as Cummins says all options on table - Australia captain Pat Cummins declined to back Warner’s place in the side for Old Trafford, while saying it would be hard to drop Marsh
Indian shuttler Lakshya Sen wins Canada Open 2023 - The 21-year-old Lakshya Sen triumphed over the reigning All England Champion Li Shi Feng by winning the first set by 21-18 and the second set by 22-20.
VHP demands fair and transparent probe into murder of Jain monk - State government urged to initiate stern action against those involved in the heinous killing and also take steps to enhance the safety and protection of religious leaders
Defence Minister Rajnath Singh discusses strengthening of bilateral ties with Malaysia’s top leadership - Rajnath Singh arrived in Kuala Lumpur on a three-day visit to Malaysia on Sunday
West Bengal panchayat election | Nadda sets up four member committee to probe poll violence - Official sources said the delegation will reach the State on July 11 and has been asked to submit its report at the earliest
Watch | Inside the iconic Kannan and Co. Goli Soda factory in Vellore - Kannan and Co. Goli Soda in Vellore district of Tamil Nadu, is successfully marching towards its 100th year. It is one of the first goli soda businesses in the Madras province in the British era.
Here are the big stories from Karnataka today - Welcome to the Karnataka Today newsletter, your guide from The Hindu on the major news stories to follow today. Curated and written by The Hindu Bureau.
Wagner boss Yevgeny Prigozhin met Russia’s Vladimir Putin after mutiny - The meeting in Moscow took place days after last month’s failed rebellion, the Kremlin says.
Migrant boat from Senegal carrying 200 people missing off Canary Islands - The aid group Walking Borders says many children are on board the missing boat, which departed from Senegal.
Dutch PM Mark Rutte to quit politics after government collapse - Mark Rutte says he will stand down after fresh elections are held in November.
Ukraine war: Poland strengthens Belarus border over Wagner fears - The prospect of Russian Wagner mercenaries moving to Belarus causes concern across the Polish border.
Zelensky honours Poles killed by Ukrainians in WW2 Volhynia massacre - Ukraine’s leader seeks to heal a deep historical wound with his Polish counterpart at a church service.
Probing the mysteries of neutron stars with a surprising earthly analog - Ultracold gases in the lab could help scientists better understand the universe. - link
Guidemaster: PC games to keep the dream alive in a cross-platform world - Only modest computer hardware is required to play these favorites. - link
How Threads’ privacy policy compares to Twitter’s (and its rivals’) - Here’s what is collected by Threads, as well as by Twitter, Bluesky, Mastodon, Spill, and Hive Social. - link
In-space manufacturing startup aces pharma experiment in orbit - One more big test remains for Varda’s first-of-its-kind “space factory.” - link
Rare case of green hairy tongue is pure nightmare fuel - The man fully recovered after extra tongue brushing. But you might not. - link
A taxi passenger tapped the driver on the shoulder to ask him a question. -
++The driver screamed, lost control of the car, nearly hit a bus, went up on the footpath, and stopped inches from a shop window. +
++For a second, everything was quiet in the cab. Then the driver said, “Look, mate, don’t ever do that again. You scared the living daylights out of me!” +
++The passenger apologized and said, “I didn’t realize that a little tap would scare you so much.” +
++The driver replied, “Sorry, it’s not really your fault. Today is my first day as a cab driver — I’ve been driving a funeral van for the last 25 years.” +
+ submitted by /u/njman10
[link] [comments]
At a crowded bus stop, a beautiful young woman in a tight leather mini skirt, with matching tight leather boots and jacket was waiting for the bus.. -
++As the bus rolled up and it became her turn to get on, she became aware that her skirt was too tight to allow her leg to come up to the height of the first step on the bus. +
++Slightly embarrassed and with a quick smile to the bus driver, she reached behind and unzipped her skirt a little, thinking that this would give her enough slack to raise her leg. +
++Again, she tried to make the step onto the bus, only to discover she still couldn’t! +
++So, a little more embarrassed, she once again reached behind and unzipped her skirt a little more and for a second time attempted the step and once again, still she could not raise her leg because of the tight skirt. +
++With a coy little smile to the driver, she again unzipped the offending skirt to give a little more slack and again was unable to make the step. +
++About this time, a big Texan that was behind her in the line picked her up easily from the waist and placed her lightly on the step of the bus. +
++Well, she went ballistic and turned on the would-be hero screeching at him, “How dare you touch my body!! I don’t even know who you are!” +
++At this, the Texan drawled, “Well ma’am normally I would agree with you, but after you unzipped my fly three times, I kinda figured that we were friends.” +
+ submitted by /u/HelpingHandsUs
[link] [comments]
Every time when I ask someone what does LGBT stand for, -
++I never get a straight answer. +
+ submitted by /u/Baffit-4100
[link] [comments]
Professor X is talking to a girl, “what is your mutant power?” -
++Girl replies: “I can guess how many pulls to turn a ceiling fan off on the first try!” +
++She points up and says: “3 pulls” +
++Professor X stands up and pulls 3 times. After the third pull the fan turns off. +
++Professor X: “Yeah thats cool and all, but not really a super power…” +
++Girl: “Yeah I was jut kidding, I can heal paraplegics” +
++Professor X, still standing: “Oh my god” +
+ submitted by /u/HelpingHandsUs
[link] [comments]
A man enters the confessional -
++He says to the priest “father, do you know that new girl who moved into town?” +
++“Kathrine? That supermodel with the blonde hair and the long legs?” +
++“That’s the one father. Well, I’ve been sleeping with her all week. We did it twice a day Monday to Friday, and then on Saturday we did it four times, and then just this morning we did it before I came here.” +
++“Oh my, and you’re not married to her?” +
++“No father.” +
++“Well do you at least know if she’s a good catholic?” +
++“She’s not a catholic at all father and neither am I.” +
++“Well if you’re not a catholic what are you doing telling me?” +
++“I’m telling everybody in town!” +
+ submitted by /u/Wolfblood-is-here
[link] [comments]